Diabetes Control and Complications Trial Research Group; NathanDM, GenuthS, LachinJ, et al.: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329:977–986.
2.
DAFNE Study Group: Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ, 2002; 325:746.
3.
BrazeauAS, MircescuH, DesjardinsK, et al.: Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. Diabetes Res Clin Pract, 2013; 99:19–23.
4.
RamotowskaA, GolickiD, DzygaloK, SzypowskaA: The effect of using the insulin pump bolus calculator compared to standard insulin dosage calculations in patients with type 1 diabetes mellitus—systematic review. Exp Clin Endocrinol Diabetes, 2013; 121:248–254.
5.
SchmidtS, MeldgaardM, SerifovskiN, et al.: Use of an automated bolus calculator in MDI-treated type 1 diabetes: the BolusCal Study, a randomized controlled pilot study. Diabetes Care, 2012; 35:984–990.
Vallejo MoraMR, CarreiraM, AnarteMT, LinaresF, OlveiraG, Gonzalez RomeroS: Bolus calculator reduces hypoglycemia in the short term and fear of hypoglycemia in the long term in subjects with type 1 diabetes (CBMDI Study). Diabetes Technol Ther, 2017; 19:000–000.
8.
Vallejo-MoraMD, Carreira-SolerM, Linares-ParradoF, et al.: The Calculating Boluses on Multiple Daily Injections (CBMDI) study: a randomized controlled trial on the effect on metabolic control of adding a bolus calculator to multiple daily injections in people with type 1 diabetes. J Diabetes, 2017; 9:24–33.
9.
ZieglerR, CavanDA, CranstonI, et al.: Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care, 2013; 36:3613–3619.
10.
GroatD, GrandoMA, SoniH, et al.: Self-management behaviors in adults on insulin pump therapy. J Diabetes Sci Technol, 2017; 11:233–239.
11.
PattonSR, DriscollKA, ClementsMA: Adherence to insulin pump behaviors in young children with type 1 diabetes mellitus. J Diabetes Sci Technol, 2017; 11:87–91.
12.
BergenstalRM, GargS, WeinzimerSA, et al.: Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA, 2016; 316:1407–1408.
13.
GargSK, WeinzimerSA, TamborlaneWV, et al.: Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2017; 19:155–163.
14.
MesserL, ForlenzaGP, WadwaRP, et al.: Hybrid Closed-Loop (HCL) therapy in adolescents and young adults with type 1 Diabetes (T1D) increases time in range (Abstract 037). Diabetes Technol Ther, 2017; 19:A13–A14.
15.
WeismanA, BaiJW, CardinezM, et al.: Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol, 2017; 5(7):501–512.
16.
El-KhatibFH, BalliroC, HillardMA, et al.: Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet, 2017; 389:369–380.
